| Literature DB >> 22319598 |
Carolin Sonne1, Lorenz Bott-Flügel, Simon Hauck, Hasema Lesevic, Petra Barthel, Fabian Michalk, Katharina Hoppe, Jörg Hausleiter, Albert Schömig, Christof Kolb.
Abstract
BACKGROUND: Post-implantation therapies to optimize cardiac resynchronization therapy (CRT) focus on adjustments of the atrio-ventricular (AV) delay and ventricular-to-ventricular (VV) interval. However, there is little consensus on how to achieve best resynchronization with these parameters. The aim of this study was to examine a novel combination of doppler echocardiography (DE) and three-dimensional echocardiography (3DE) for individualized optimization of device based AV delays and VV intervals compared to empiric programming.Entities:
Mesh:
Year: 2012 PMID: 22319598 PMCID: PMC3272028 DOI: 10.1371/journal.pone.0030964
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 13D-echocardiography guided optimization of cardiac resynchronization therapy.
Patient with ischemic cardiomyopathy, severly reduced systolic left ventricular (LV)-function (EF 16.8%), left bundle branch block and dyspnea on exertion (NYHA class III) selected for cardiac resynchronisation therapy (CRT) before biventricular pacemaker implantation: A) tracing of the LV endocardial boundary in the multiple apical and short axis views. From these datasets a volumetric model of the left ventricle is drawn (B), and time-volume curves are automatically integrated for each segment: C) time-volume curves of the patient before pacemaker implantation (upper panel); immediately after implantation (middle panel); after complete echocardiographic optimization (lower panel). Shown are the respective SDI values after each optimization step.
Baseline characteristics.
| N = 25 | |
| Demographic data | |
| Age, years | 67±11 |
| Male sex | 14 (56%) |
|
| |
| NYHA class 3 | 22 (88%) |
| NYHA class 4 | 3 (12%) |
| Ischemic CMP | 14 (56%) |
|
| |
| Betablockers | 23 (92%) |
| ACE-inhibitors/ARBs | 23 (92%) |
| Diuretics | 24 (96%) |
| Aldosterone antagonists | 18 (72%) |
| Digitalis | 3 (12%) |
| Statins | 25 (100%) |
|
| |
| QRS width, ms (median; IQR) | 160 (122–198) |
|
| |
| LV end-diastolic volume, ml | 176±62 |
| LV end-systolic volume, ml | 138±60 |
| LVEF, % | 23±7 |
| SDI, % | 14.3±5.5 |
Values are shown as means ± standard deviation or count (percentage).
NYHA, New York Heart Association; CMP, cardiomyopathy; ACE, Angiotensin-converting enzyme; ARB, Angiotensin receptor blocker; LV, left ventricle; SDI, systolic dyssynchrony index.
Echocardiographic parameters at baseline and after AV delay and VV interval optimization.
| Baseline | After AV delay optimization | After complete optimization | |
| LV end-diastolic volume, ml | 176±62 | 168±50 | 166±48 |
| LV end-systolic volume, ml | 138±60 | 121±48 | 115±42 |
|
| 23±7 | 30±8 | 32±8 |
|
| 14.3±5.5 | 9.0±4. | 6.1±2.6 |
|
| 24±7 | 27±9 | 26±8 |
SDI, systolic dyssynchrony index; AV, atrio-ventricular; VV, ventriculo-ventricular; LV, left ventricular; VTI, velocity-time integral.
Shown are means ± standard deviation.
p<0.001: for comparison of AV optimization vs baseline.
p<0.05: for comparison of complete optimization vs AV optimization only.
*p<0.05: for comparison of complete optimization vs baseline.
Figure 2Acute hemodynamic effects of 3D-echocardiography guided optimization.
Hemodynamic variables for each timestep of the optimization protocol: A) systolic dyssynchrony index, B) ejection fraction, and C) left-ventricular end-diastolic and end-systolic volumes. Shown are means ± standard deviation. * p<0.05 vs. baseline values.
Figure 3Ventricular-to-ventricular (VV) intervals in patients with ischemic and dilated cardiomyopathy.
Number of patients with simultaneous activation of left and right ventricle or sequential inter-ventricular pacing depending on ischemic or dilated cardiomyopathy.